Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma.

Literature DB >> 28149872

Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma.

Ioannis Panagiotidis¹, Dimitrios Christoulas², Evangelos Terpos¹.

Abstract

Entities: Disease Gene

Year: 2016 PMID： 28149872 PMCID： PMC5233538 DOI： 10.21037/atm.2016.11.75

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

24 in total

Review 1. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors: S Bielack; D Carrle; P G Casali
Journal: Ann Oncol Date: 2009-05 Impact factor: 32.976

Review 2. The role of radiotherapy in oseosarcoma.

Authors: Rudolf Schwarz; Oyvind Bruland; Anna Cassoni; Paula Schomberg; Stefan Bielack
Journal: Cancer Treat Res Date: 2009

3. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

Authors: David Thomas; Robert Henshaw; Keith Skubitz; Sant Chawla; Arthur Staddon; Jean-Yves Blay; Martine Roudier; Judy Smith; Zhishen Ye; Winnie Sohn; Roger Dansey; Susie Jun
Journal: Lancet Oncol Date: 2010-02-10 Impact factor: 41.316

4. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors: Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544

5. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999.

Authors: Gaetano Bacci; Stefano Ferrari; Mario Mercuri; Alessandra Longhi; Nicola Fabbri; Stefano Galletti; Cristiana Forni; Alba Balladelli; Massimo Serra; Piero Picci
Journal: Acta Orthop Date: 2007-06 Impact factor: 3.717

6. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.

Authors: N Bodmer; D K Walters; B Fuchs
Journal: Pediatr Blood Cancer Date: 2008-04 Impact factor: 3.167

2. The Role of the Clinical Pharmacist on the Health Outcomes of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD).

Authors: Yanqing Gong; Qiying Chen; Yin Zhang
Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-08-15

2 in total

Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma.

Review 1. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Review 2. The role of radiotherapy in oseosarcoma.

3. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

4. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

5. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999.

6. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.

Review 7. RANKL inhibition for the management of patients with benign metabolic bone disorders.

8. The molecular pathogenesis of osteosarcoma: a review.

9. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.

10. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.

Review 1. A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

2. The Role of the Clinical Pharmacist on the Health Outcomes of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD).